Li Shu1, Qianhua Xu2, Qingxia Meng3, Xue Dai4, Yun Zhang5, Wei Zhou6, Honggang Yi7, Jinyong Liu1, Chunxiang Wu1, Zhen Hou1, Yugui Cui1, Tin Chiu Li8, Jiayin Liu1. 1. Center of Clinical Reproductive Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. 2. Center of Reproductive Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. 3. Center of Reproductive Genetics, Suzhou Municipal Hospital, Suzhou 215000, Chin. 4. Center of Reproduction, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China. 5. Center of Reproduction, Wuxi Maternal and Child Health Care Hospital, Wuxi 214000, China. 6. Center of Reproductive Medicine, Changzhou Maternal and Child Health Care Hospital, Changzhou 213000, China. 7. Statistics Department, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. 8. Reproductive Medicine and Surgery Unit, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China.
Abstract
BACKGROUND: This clinical trial aimed to compare the clinical efficacy of highly purified human menopausal gonadotropin (HP-HMG) plus recombinant human follicle-stimulating hormone (rFSH) versus rFSH alone on controlled ovarian stimulation (COS) in vitro fertilization-embryo transfer (IVF-ET). METHODS: A total of 610 women underwent long gonadotropin-releasing hormone (GnRH) agonist protocol for IVF treatment. The subjects were randomized into 2 groups: HP-HMG + rFSH group (n=305) and rFSH group (n=305). The main outcome was the progesterone (P) level on the day of HCG injection. RESULTS: There was no significant difference in terms of the demographic and baseline characters between the two groups. In rFSH group, the P level on the day of HCG trigger were significantly higher than that of HP-HMG+rFSH group (4.3±2.2 vs. 3.8±1.7 nmol/L, P<0.001). The fertilization rate in rFSH group was significantly lower than that of HP-HMG + rFSH group (69.2% vs. 73.9%, P<0.001). Simultaneously, the percentage of cycles with fresh embryo transfer in rFSH group was also significantly lower than that of HP-HMG + rFSH group (49.6% vs. 57.5%, P=0.007). However, there was no difference in terms of cleavage rate, implantation rate, clinical pregnancy rate and ovarian hyperstimulation syndrome (OHSS) rate between two groups. CONCLUSIONS: The use of combined HP-HMG with FSH may be superior to rFSH alone in stimulating the ovary in normal responders undergoing IVF treatment. Furthermore, the further prospective studies with large sample are still needed to confirm the study.
BACKGROUND: This clinical trial aimed to compare the clinical efficacy of highly purified human menopausal gonadotropin (HP-HMG) plus recombinant human follicle-stimulating hormone (rFSH) versus rFSH alone on controlled ovarian stimulation (COS) in vitro fertilization-embryo transfer (IVF-ET). METHODS: A total of 610 women underwent long gonadotropin-releasing hormone (GnRH) agonist protocol for IVF treatment. The subjects were randomized into 2 groups: HP-HMG + rFSH group (n=305) and rFSH group (n=305). The main outcome was the progesterone (P) level on the day of HCG injection. RESULTS: There was no significant difference in terms of the demographic and baseline characters between the two groups. In rFSH group, the P level on the day of HCG trigger were significantly higher than that of HP-HMG+rFSH group (4.3±2.2 vs. 3.8±1.7 nmol/L, P<0.001). The fertilization rate in rFSH group was significantly lower than that of HP-HMG + rFSH group (69.2% vs. 73.9%, P<0.001). Simultaneously, the percentage of cycles with fresh embryo transfer in rFSH group was also significantly lower than that of HP-HMG + rFSH group (49.6% vs. 57.5%, P=0.007). However, there was no difference in terms of cleavage rate, implantation rate, clinical pregnancy rate and ovarian hyperstimulation syndrome (OHSS) rate between two groups. CONCLUSIONS: The use of combined HP-HMG with FSH may be superior to rFSH alone in stimulating the ovary in normal responders undergoing IVF treatment. Furthermore, the further prospective studies with large sample are still needed to confirm the study.
Entities:
Keywords:
In vitro fertilization (IVF); highly purified human menopausal gonadotropin (HP-HMG); pregnancy; progesterone; recombinant human follicle-stimulating hormone (rFSH)
Authors: M Filicori; G E Cognigni; S Taraborrelli; D Spettoli; W Ciampaglia; C Tabarelli De Fatis; P Pocognoli; B Cantelli; S Boschi Journal: J Clin Endocrinol Metab Date: 2001-01 Impact factor: 5.958
Authors: G De Placido; A Mollo; C Alviggi; I Strina; M T Varricchio; A Ranieri; N Colacurci; A Tolino; M Wilding Journal: Hum Reprod Date: 2001-09 Impact factor: 6.918
Authors: Arri Coomarasamy; Masoud Afnan; Deepti Cheema; Fulco van der Veen; Patrick M M Bossuyt; Madelon van Wely Journal: Hum Reprod Date: 2007-12-03 Impact factor: 6.918